Becton, Dickinson and Company (NYSE:BDX) Updates FY 2024 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) issued an update on its FY 2024 earnings guidance on Friday morning. The company provided earnings per share guidance of 12.950-13.150 for the period, compared to the consensus earnings per share estimate of 12.950. The company issued revenue guidance of $20.1 billion-$20.3 billion, compared to the consensus revenue estimate of $20.3 billion.

Analyst Ratings Changes

Separately, Barclays boosted their target price on Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an overweight rating in a research note on Monday, February 5th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, Becton, Dickinson and Company presently has a consensus rating of Moderate Buy and an average price target of $280.00.

Becton, Dickinson and Company Trading Down 2.4 %

Shares of NYSE:BDX traded down $5.73 during midday trading on Friday, hitting $234.62. 1,722,348 shares of the stock traded hands, compared to its average volume of 1,413,846. The company has a quick ratio of 0.64, a current ratio of 1.08 and a debt-to-equity ratio of 0.56. The business's 50 day moving average is $238.68 and its two-hundred day moving average is $240.71. The stock has a market capitalization of $67.78 billion, a PE ratio of 55.61, a P/E/G ratio of 1.93 and a beta of 0.45. Becton, Dickinson and Company has a one year low of $229.40 and a one year high of $287.32.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, beating analysts' consensus estimates of $2.97 by $0.20. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. The business had revenue of $5.05 billion during the quarter, compared to analyst estimates of $5.04 billion. During the same quarter in the prior year, the company posted $2.86 EPS. Becton, Dickinson and Company's quarterly revenue was up 4.6% compared to the same quarter last year. As a group, research analysts forecast that Becton, Dickinson and Company will post 12.94 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Monday, June 10th will be issued a $0.95 dividend. The ex-dividend date of this dividend is Monday, June 10th. This represents a $3.80 annualized dividend and a yield of 1.62%. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 90.05%.

Insider Activity

In related news, SVP Thomas J. Spoerel sold 282 shares of the stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the completion of the transaction, the senior vice president now directly owns 2,276 shares of the company's stock, valued at $542,348.04. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the company's stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the transaction, the senior vice president now owns 2,276 shares in the company, valued at approximately $542,348.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael David Garrison sold 1,715 shares of the firm's stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total value of $399,269.15. Following the completion of the transaction, the executive vice president now owns 5,381 shares of the company's stock, valued at approximately $1,252,750.61. The disclosure for this sale can be found here. Insiders own 0.31% of the company's stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.